We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FPRX
2651
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $264K | ﹤0.01% |
57,433
+243
| +0.4% | +$962 |
|
2652
Alpha Metallurgical Resources
AMR
$1.76B
| $263K | ﹤0.01% |
29,088
+190
| +0.7% | +$2.89K |
|
|
UBX
2653
DELISTED
Unity Biotechnology
UBX
| $263K | ﹤0.01% |
3,654
+44
| +1% | +$3.1K |
|
|
WORK
2654
DELISTED
Slack Technologies, Inc.
WORK
| $262K | ﹤0.01% |
+11,671
| New | +$260K |
|
2655
Mid Penn Bancorp
MPB
$970M
| $261K | ﹤0.01% |
9,059
+43
| +0.5% | +$1.14K |
|
2656
Toyota
TM
$224B
| $261K | ﹤0.01% |
1,856
-168
| -8% | -$23.5K |
|
2657
Alphatec Holdings
ATEC
$1.59B
| $260K | ﹤0.01% |
36,648
+6,390
| +21% | +$41K |
|
2658
Bassett Furniture
BSET
$169M
| $260K | ﹤0.01% |
15,566
-567
| -4% | -$8.79K |
|
2659
Fidelity D&D Bancorp
FDBC
$313M
| $260K | ﹤0.01% |
4,173
-22
| -0.5% | -$1.43K |
|
|
UBFO
2660
DELISTED
United Security Bancshares
UBFO
| $260K | ﹤0.01% |
24,271
-55
| -0.2% | -$572 |
|
2661
Energy Fuels
UUUU
$3.21B
| $260K | ﹤0.01% |
136,263
+2,744
| +2% | +$5.4K |
|
2662
Covenant Logistics
CVLG
$888M
| $259K | ﹤0.01% |
40,144
+292
| +0.7% | +$2.12K |
|
2663
First Northwest Bancorp
FNWB
$107M
| $259K | ﹤0.01% |
14,261
+108
| +0.8% | +$1.9K |
|
|
MLVF
2664
DELISTED
Malvern Bancorp, Inc.
MLVF
| $259K | ﹤0.01% |
11,210
+24
| +0.2% | +$543 |
|
|
GPX
2665
DELISTED
GP Strategies Corp.
GPX
| $259K | ﹤0.01% |
19,606
+51
| +0.3% | +$633 |
|
2666
Entravision Communication
EVC
$1.02B
| $258K | ﹤0.01% |
98,340
-245
| -0.2% | -$669 |
|
|
CCRD
2667
DELISTED
CoreCard
CCRD
| $256K | ﹤0.01% |
6,411
+125
| +2% | +$5.42K |
|
2668
TSMC
TSM
$2.16T
| $256K | ﹤0.01% |
4,400
| – | – |
|
2669
NI Holdings
NODK
$318M
| $255K | ﹤0.01% |
14,843
-59
| -0.4% | -$1.01K |
|
|
FARM
2670
DELISTED
Farmer Brothers
FARM
| $254K | ﹤0.01% |
16,846
+165
| +1% | +$2.41K |
|
|
GRTS
2671
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $254K | ﹤0.01% |
28,303
+250
| +0.9% | +$2.08K |
|
2672
Alico
ALCO
$283M
| $252K | ﹤0.01% |
7,020
-27
| -0.4% | -$908 |
|
2673
First Capital
FCAP
$222M
| $252K | ﹤0.01% |
+3,457
| New | +$217K |
|
|
ARA
2674
DELISTED
American Renal Associates Holdings, Inc
ARA
| $252K | ﹤0.01% |
24,276
+179
| +0.7% | +$1.53K |
|
|
PARAA
2675
DELISTED
Paramount Global Class A
PARAA
| $250K | ﹤0.01% |
+5,579
| New | +$236K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.